Clinical trials: Advanced HBV-Related Hepatocellular Carcinoma, open to volunteers
Hepatocellular Carcinoma, Liver Cancer, Adult
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT05195294
- Testing
- LioCyx-M, Lenvatinib
- Volunteers
- 55 people
- Sponsor
- Lion TCR Pte. Ltd.
HBV-HCC, Unresectable Advanced HBV-related Liver Cancer
Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
This study is a prospective, real-world study intended to evaluate the efficacy and safety of pegylated interferon alpha-2b (PegIntron®) combined with targeted immunotherapy in patients with unresectable intermediate and advanced…
- Trial name
- NCT07769827
- Testing
- Combined Peg IFNα-2b treatment group
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Jinling Hospital, China
Advanced HBV-Related Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
This early phase (Phase 1) study will evaluate BRII 5395, administered in combination with two approved anticancer agents, sintilimab and bevacizumab, in patients with advanced liver cancer caused by chronic hepatitis B virus…
- Trial name
- NCT07557251
- Testing
- BRII-5395, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences